印度胃肠胰神经内分泌肿瘤（GEP-NETs）的诊断趋势：基于网络注册库的多中心数据报告
Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
作者信息
Palepu Jagannath, Shrikhande Shailesh V, Bhaduri Debanshu, Shah Rajiv C, Sirohi Bhawna, Chhabra Verushka, Dhar Puneet, Sastry Regulagedda, Sikora Sadiq
机构信息
Department of Surgical Oncology, Lilavati Hospital and Research Centre, A-791, Bandra Reclamation, K C Road, Bandra West, Mumbai, 400 050, India.
Department of Gastrointestinal and HPB Surgery, Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai, 400 012, India.
出版信息
Indian J Gastroenterol. 2017 Nov;36(6):445-451. doi: 10.1007/s12664-017-0808-7. Epub 2018 Feb 19.
INTRODUCTION
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors. We report data of 407 GEP-NET cases from a neuroendocrine tumor (NET) registry in India.
METHODS
The AP-NET registry is an open-label, multicenter, longitudinal observational registry of patients with GEP-NETs in which six tertiary care oncology centers contributed data. Data was prospectively entered in a dedicated computerized database and was reviewed retrospectively. The patients were divided into three cohorts-those diagnosed from 2001 to 2005, from 2006 to 2010, and from 2011 to 2016.
RESULTS
Of the 407 cases registered, 37 were in Cohort I, 136 in Cohort II, and 234 in Cohort III. Majority were symptomatic with only 98 patients (24.0%) asymptomatic. The most common presentation of non-functional tumors was abdominal pain (42.4%), while functional tumors presented most commonly with carcinoid syndrome. Use of DOTA-PET, introduced in 2011, has increased evaluation in 33.3% patients in Cohort III. The most common primary site was pancreas in all three cohorts. Male preponderance (58.3%) was seen. Histopathological grading was obtained in 230 (56.5%) patients-118 (29%) Grade I, 74 (18.2%) Grade II, and 36 (8.8%) Grade III NET.
CONCLUSION
This report highlights changing trends in the diagnosis and reporting of NETs over the last 15 years.
引言
胃肠胰神经内分泌肿瘤（GEP-NETs）是罕见肿瘤。我们报告了来自印度一个神经内分泌肿瘤（NET）登记处的407例GEP-NET病例的数据。
方法
AP-NET登记处是一个关于GEP-NET患者的开放标签、多中心、纵向观察登记处，六个三级肿瘤护理中心提供了数据。数据前瞻性地录入一个专用的计算机化数据库，并进行回顾性审查。患者被分为三个队列——2001年至2005年诊断的患者、2006年至2010年诊断的患者以及2011年至2016年诊断的患者。
结果
在登记的407例病例中，队列I有37例，队列II有136例，队列III有234例。大多数患者有症状，只有98例（24.0%）无症状。无功能肿瘤最常见的表现是腹痛（42.4%），而功能性肿瘤最常见的表现是类癌综合征。2011年引入的DOTA-PET使队列III中33.3%的患者的评估有所增加。所有三个队列中最常见的原发部位是胰腺。男性占优势（58.3%）。230例（56.5%）患者获得了组织病理学分级——118例（29%）为I级，74例（18.2%）为II级，36例（8.8%）为III级NET。
结论
本报告强调了过去15年中NET诊断和报告的变化趋势。
Zotero 插件